About Choksi Laboratories
Choksi Laboratories is a publicly listed company based in Indore (India) founded in 1982. Laboratory services for pharmaceutical and food analysis are provided. The company has 349 employees. Its Indian entity Choksi Laboratories Limited reported revenue of ₹46.98 Cr. Its focus areas include Medical Research Labs.
Company details
Provider of pharmaceutical and food analysis laboratory services. It offers analysis, calibration, pollution control, research, and consultancy services to various industries. A key competency is contract laboratory services for pharmaceutical quality control and quality assurance, addressing regulatory norms set by various standards bodies. The company assists organizations in achieving high quality standards in products, processes, and personnel. Services include sample submission and quotation requests for analysis.
- Headquarters Indore, India
- Employees 349
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website choksilab.com
- Legal Name Choksi Laboratories Limited
- Market Cap₹137 Cr
CHOKSILA · BSE
- Share Price₹195.00
-0.51% today
- Revenue₹46.01 Cr
FY 2025-26 · +10.1% YoY
- EBITDA₹12.18 Cr
Margin 26.5%
- Net Profit₹1.04 Cr
FY 2025-26 · -31.6% YoY
- P/E (TTM)72.8x
P/B 5.4x
- ROE4.2%
ROCE 9.1%
- Debt / Equity1.29
Interest cover 56.2x
- Employee Count349
Associated legal entities of Choksi Laboratories
Choksi Laboratories operates through Choksi Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Choksi Laboratories Limited Listed CIN L85195MP1993PLC007471 | Active | 29 Jan 1993 | Indore, Madhya Pradesh | ₹47.0 Cr | 318 | 10 | View details |
Board of directors of Choksi Laboratories Limited (Choksi Laboratories)
Choksi Laboratories Limited is the primary company behind Choksi Laboratories. The board of Choksi Laboratories Limited currently have 8 directors; the longest-serving is Sunil Kumar Choksi, appointed in 2008. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sunil Kumar Choksi DIN 00155078 | Managing Director | 01 Sep 2008 | 18 yrs 2 mo | Choksi Laboratories Limited |
| Vyangesh Choksi DIN 00154926 | Whole-time director | 01 Aug 2009 | 17 yrs 3 mo | Choksi Laboratories Limited |
| Stela Choksi DIN 00155043 | Whole-time director | 01 Apr 2011 | 15 yrs 7 mo | Choksi Laboratories Limited |
| Himika Choksi DIN 00155007 | Whole-time director | 01 Mar 2017 | 9 yrs 8 mo | Choksi Laboratories Limited |
| Raghmendra Singh DIN 08459665 | Director | 13 Aug 2022 | 4 yrs 3 mo | Choksi Laboratories Limited |
| Prachi Mantri DIN 10491114 | Director | 03 Feb 2024 | 2 yrs 9 mo | Choksi Laboratories Limited |
| Abha Shastri DIN 00065772 | Director | 01 Apr 2024 | 2 yrs 7 mo | Choksi Laboratories Limited |
| Ritik Pavecha DIN 08790431 | Director | 07 Feb 2026 | 9 mo | Choksi Laboratories Limited |
IPO & Listings of Choksi Laboratories
Choksi Laboratories is a publicly listed company on the BSE with ticker symbol CHOKSILA in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Oct 2001
- Listed onBSE: 526546
- Listed entityChoksi Laboratories Limited
- Exchange sectorCommercial services
- ISININE493D01013
- Share price₹216.65 (+4.26% on the day) · 2026-10-14
- Market capitalisation₹145 Cr
- Price to earnings69.8
- EPS (diluted, trailing year)₹3.10
- Volume (last session)28,204
Financials of Choksi Laboratories
Exchange-reported figures of Choksi Laboratories Limited, the listed company behind Choksi Laboratories (BSE: CHOKSILA).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 46.01 | 41.78 | 36.70 | 34.44 | 30.04 | 25.69 | 28.16 |
| Revenue growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | - |
| EBITDA | 12.18 | 11.30 | 10.27 | 9.70 | 8.90 | 4.12 | 0.41 |
| EBITDA margin | +26.5% | +27.1% | +28.0% | +28.2% | +29.6% | +16.0% | +1.5% |
| Profit before tax | 3.20 | 2.15 | 1.66 | 3.72 | 0.36 | (2.81) | (5.71) |
| Net profit | 1.04 | 1.52 | 1.11 | 1.64 | 0.20 | (2.62) | (0.75) |
| Net profit margin | +2.3% | +3.6% | +3.0% | +4.8% | +0.7% | -10.2% | -2.7% |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Balance sheet | |||||||
| Total assets | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Net worth | 25.58 | 23.61 | 22.22 | 21.11 | 17.91 | 17.75 | 20.23 |
| Total debt | 34.17 | 29.15 | 30.87 | 32.41 | 37.29 | 39.15 | 31.64 |
| Cash & bank | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Net working capital | 8.80 | 5.64 | 7.52 | 8.64 | 6.18 | 4.61 | 6.36 |
| Cash flow | |||||||
| Cash from operations | 7.86 | 11.78 | 11.55 | 8.25 | 7.88 | 5.90 | 2.87 |
| Cash from investing | (7.07) | (7.61) | (6.65) | (0.71) | (2.71) | (7.65) | (13.76) |
| Cash from financing | (1.20) | (4.22) | (4.58) | (7.61) | (5.07) | 1.63 | 11.09 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06 | 12.82 | 10.82 | 11.12 | 11.24 | 11.40 | 10.38 | 9.26 |
| Revenue growth (YoY) | +7.3% | +12.5% | +4.2% | +20.1% | +4.7% | - | - | - |
| Other income | 0.02 | 0.06 | 0.89 | 0.01 | 0.00 | 0.04 | 0.01 | 0.01 |
| Total expenses | 8.78 | 9.18 | 8.17 | 8.19 | 8.34 | 7.90 | 7.84 | 6.90 |
| EBITDA | 3.28 | 3.64 | 2.65 | 2.93 | 2.90 | 3.50 | 2.54 | 2.36 |
| EBITDA margin | +27.2% | +28.4% | +24.5% | +26.3% | +25.8% | +30.7% | +24.5% | +25.5% |
| Depreciation | 1.97 | 1.89 | 1.83 | 1.69 | 1.68 | 1.70 | 1.68 | 1.61 |
| Interest | 0.73 | 0.71 | 0.81 | 0.69 | 0.60 | 0.58 | 0.69 | 0.66 |
| Profit before tax | 0.60 | 1.10 | 0.90 | 0.56 | 0.62 | 1.26 | 0.18 | 0.10 |
| Tax | 0.02 | 0.07 | 0.59 | 0.32 | 0.24 | 0.34 | 0.08 | 0.02 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06 | 12.82 | 10.82 | 11.12 | 11.24 | 11.40 | 10.38 | 9.26 |
| Revenue growth (YoY) | +7.3% | +12.5% | +4.2% | +20.1% | +4.7% | - | - | - |
| Other income | 0.02 | 0.06 | 0.89 | 0.01 | 0.00 | 0.04 | 0.01 | 0.01 |
| Total expenses | 8.78 | 9.18 | 8.17 | 8.19 | 8.34 | 7.90 | 7.84 | 6.90 |
| EBITDA | 3.28 | 3.64 | 2.65 | 2.93 | 2.90 | 3.50 | 2.54 | 2.36 |
| EBITDA margin | +27.2% | +28.4% | +24.5% | +26.3% | +25.8% | +30.7% | +24.5% | +25.5% |
| Depreciation | 1.97 | 1.89 | 1.83 | 1.69 | 1.68 | 1.70 | 1.68 | 1.61 |
| Interest | 0.73 | 0.71 | 0.81 | 0.69 | 0.60 | 0.58 | 0.69 | 0.66 |
| Profit before tax | 0.60 | 1.10 | 0.90 | 0.56 | 0.62 | 1.26 | 0.18 | 0.10 |
| Tax | 0.02 | 0.07 | 0.59 | 0.32 | 0.24 | 0.34 | 0.08 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 46.01 | 41.78 | 36.70 | 34.44 | 30.04 | 25.69 | 28.16 |
| Revenue growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | - |
| Other income | 0.97 | 0.07 | 0.16 | 3.04 | 0.12 | 0.49 | 0.33 |
| Total expenses | 33.83 | 30.48 | 26.43 | 24.74 | 21.14 | 21.57 | 27.75 |
| Employee cost | 16.62 | 15.22 | 13.03 | 12.00 | 11.04 | 10.78 | 11.70 |
| EBITDA | 12.18 | 11.30 | 10.27 | 9.70 | 8.90 | 4.12 | 0.41 |
| EBITDA margin | +26.5% | +27.1% | +28.0% | +28.2% | +29.6% | +16.0% | +1.5% |
| Depreciation | 7.09 | 6.50 | 5.71 | 5.50 | 5.43 | 4.60 | 4.56 |
| Interest | 2.86 | 2.72 | 3.06 | 3.52 | 3.23 | 2.82 | 1.89 |
| Profit before tax | 3.20 | 2.15 | 1.66 | 3.72 | 0.36 | (2.81) | (5.71) |
| Tax | 1.23 | 0.63 | 0.55 | 0.51 | 0.16 | (0.20) | (1.83) |
| Net profit | 1.04 | 1.52 | 1.11 | 1.64 | 0.20 | (2.62) | (0.75) |
| Net profit margin | +2.3% | +3.6% | +3.0% | +4.8% | +0.7% | -10.2% | -2.7% |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves & surplus | 18.61 | 16.64 | 15.25 | 14.14 | 10.94 | 10.78 | 13.26 |
| Shareholders' funds (net worth) | 25.58 | 23.61 | 22.22 | 21.11 | 17.91 | 17.75 | 20.23 |
| Secured loans | 27.83 | 28.07 | 29.27 | 30.35 | 33.77 | 35.14 | 30.36 |
| Unsecured loans | 6.34 | 1.08 | 1.60 | 2.06 | 3.52 | 4.01 | 1.28 |
| Total debt | 34.17 | 29.15 | 30.87 | 32.41 | 37.29 | 39.15 | 31.64 |
| Total liabilities | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Assets | |||||||
| Gross block | 94.13 | 84.72 | 74.31 | 70.94 | 68.71 | 67.56 | 45.94 |
| Net block | 51.55 | 47.62 | 43.44 | 44.83 | 46.56 | 50.32 | 33.08 |
| Capital work in progress | 0.40 | 0.00 | 2.99 | 0.31 | 1.67 | 0.50 | 13.06 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.24 | 0.56 | 0.36 | 0.21 | 0.25 | 0.11 | 0.18 |
| Sundry debtors | 14.73 | 11.27 | 10.39 | 10.65 | 10.29 | 8.16 | 6.99 |
| Cash & bank balances | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Loans & advances | 3.70 | 3.88 | 3.16 | 2.75 | 3.06 | 4.45 | 8.95 |
| Total current assets | 18.88 | 16.32 | 14.57 | 13.95 | 14.01 | 13.03 | 16.55 |
| Total current liabilities | 10.08 | 10.68 | 7.05 | 5.31 | 7.83 | 8.42 | 10.19 |
| Net working capital | 8.80 | 5.64 | 7.52 | 8.64 | 6.18 | 4.61 | 6.36 |
| Total assets | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 | 0.23 |
| Net cash from operating activities | 7.86 | 11.78 | 11.55 | 8.25 | 7.88 | 5.90 | 2.87 |
| Net cash from investing activities | (7.07) | (7.61) | (6.65) | (0.71) | (2.71) | (7.65) | (13.76) |
| Net cash from financing activities | (1.20) | (4.22) | (4.58) | (7.61) | (5.07) | 1.63 | 11.09 |
| Net change in cash | (0.41) | (0.04) | 0.32 | (0.07) | 0.10 | (0.12) | 0.20 |
| Closing cash | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | - |
| EBITDA growth | +7.8% | +10.0% | +5.9% | +9.0% | +116.0% | +904.9% | - |
| PBT growth | +48.8% | +29.5% | -55.4% | +933.3% | +9998.0% | +50.8% | - |
| Net income growth | -31.6% | +36.9% | -32.3% | +720.0% | +107.6% | -249.3% | - |
| Revenue CAGR (3Y) | +10.1% | +11.6% | +12.6% | +6.9% | -3.8% | -5.5% | -0.7% |
| EBITDA CAGR (3Y) | +7.9% | +8.3% | +35.6% | +187.1% | +7.0% | -13.4% | -55.9% |
| Profitability & leverage | |||||||
| Net income margin | +4.3% | +3.6% | +3.0% | +9.3% | +0.7% | -10.2% | -13.8% |
| Return on capital employed | +9.1% | +8.9% | +8.6% | +8.9% | +6.3% | +0.0% | -1.4% |
| Return on net worth | +4.2% | +6.6% | +5.1% | +8.4% | +1.2% | -13.7% | -3.4% |
| Debt / equity | 1.29 | 1.31 | 1.46 | 1.79 | 2.14 | 1.86 | 1.10 |
| Long-term debt / equity | 0.75 | 0.76 | 1.02 | 1.45 | 1.79 | 1.59 | 0.95 |
| Interest cover | 56.19 | 56.67 | 67.11 | 83.81 | 93.08 | -587.50 | -45.54 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.51 | 0.53 | 0.51 | 0.49 | 0.44 | 0.45 | 0.62 |
| Inventory turnover | 115.03 | 90.83 | 128.77 | 149.74 | 166.89 | 177.17 | 95.46 |
| Debtors turnover | 3.54 | 3.86 | 3.49 | 3.29 | 3.26 | 3.39 | 3.57 |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 36.72 | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 | 29.03 |
Web traffic of Choksi Laboratories
Websites that share an audience with Choksi Laboratories (choksilab.com).
Websites whose visitors overlap most with Choksi Laboratories. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
shreejilaboratory.com | shreejilaboratory.com | 100% | #12,153,354 | – |
Top companies in Clinical Trials & Research Tech
2 companies that operate in the same segment as Choksi Laboratories (Clinical Trials & Research Tech) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | 2004 | Ahmedabad, Gujarat, India | USD 74.68 M | 1,618 | ||
Generic injectables for oncology and anesthesiology are manufactured. | 1989 | Hyderabad, Telangana, India | USD 4.22 M | 228 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Choksi Laboratories
Complete news archive for Choksi Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Choksi Laboratories
Choksi Laboratories was founded in 1982.
Choksi Laboratories is headquartered in Indore, India. It is registered at Indore, Madhya Pradesh, India.
Choksi Laboratories has 349 employees.
The primary company behind Choksi Laboratories, Choksi Laboratories Limited, reported revenue of ₹46.98 Cr for FY 2026, up 10% year on year.
Provider of pharmaceutical and food analysis laboratory services. It offers analysis, calibration, pollution control, research, and consultancy services to various industries. A key competency is contract laboratory services for pharmaceutical quality control and quality assurance, addressing regulatory norms set by various standards bodies. The company assists organizations in achieving high quality standards in products, processes, and personnel. Services include sample submission and quotation requests for analysis.
Yes, Choksi Laboratories is publicly traded on BSE under the ticker symbol CHOKSILA.
Choksi Laboratories operates through Choksi Laboratories Limited.
The legal entities of Choksi Laboratories currently have 9 directors, including Himika Choksi, Raghmendra Singh, Vyangesh Choksi and others.